Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

Fosun Pharmaceutical is a spinoff from Fosun International, which is chaired by China billionaire chairman Guo Guangchang; ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizeable potential payout down the line. | Seattle’s Adaptive ...

Pfizer announced it has entered into an exclusive global collaboration and license agreement with Chongqing Yao ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Dec 9 (Reuters) - Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of ...

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...